CEL SCI CORP: insider trades · United States · SEC (Form 4)

About CEL SCI CORP

CEL-SCI Corp. (ticker: CVM) is a U.S.-listed biotechnology company traded on NYSE American, making it a small-cap healthcare name with high clinical and financing risk. The company was incorporated in 1983 in Colorado and is now headquartered in Vienna, Virginia, United States. Its business model is centered on research and development rather than commercial operations, with an almost singular focus on cancer immunotherapy. CEL-SCI’s lead program is Multikine (Leukocyte Interleukin, Injection), an investigational immunotherapy being developed primarily for advanced, previously untreated head and neck cancer. According to the latest SEC filings, Multikine is intended to be administered locally at the tumor site soon after diagnosis and before surgery or radiation, with the goal of stimulating an anti-tumor immune response while the immune system is still intact. The company also describes a manufacturing footprint near Baltimore, Maryland, that has been developed in anticipation of potential commercialization. From a competitive standpoint, CEL-SCI occupies a narrow niche. It does not yet have a diversified commercial portfolio or meaningful recurring product revenue, so the equity story is driven mainly by clinical progress, regulatory milestones, and access to capital. In oncology immunotherapy, competition is intense, with large pharmaceutical companies and numerous biotech peers pursuing alternative mechanisms and combinations. CEL-SCI’s differentiation lies in Multikine’s distinct treatment timing and cytokine-based design, but the execution risk remains substantial. Recent company developments include continued work on the Multikine program, ongoing regulatory and partnering activity outside the United States, and an August 2025 Breakthrough Medicine Designation application submitted to the Saudi Food and Drug Authority for Multikine in Saudi Arabia through Dallah Pharma. Recent SEC disclosures also emphasize that CEL-SCI remains a late clinical-stage company with no approved products and continued dependence on external financing. For investors in French-speaking markets, CVM is therefore best viewed as a highly speculative biotech single-asset story: potentially meaningful upside if the program advances, but also elevated dilution risk and high sensitivity to clinical and regulatory news.